论文部分内容阅读
[目的]探讨紫杉醇联合铂类周疗与月疗治疗卵巢上皮癌的疗效及毒副反应。[方法]2000年2月～12月 ,31例晚期卵巢上皮癌患者入组 ,其中周疗15例 ,Taxol60mg/m2～80mg/m2静脉滴注每周重复 ,连续3周 ,休息1周为一疗程 ,月疗16例 ,Taxol135mg/m2～175mg/m2静脉滴注4周重复 ,铂类用法两组相同 ,PDD70mg/m2或CBPAUC4～5,4周重复。初次治疗13例 ,手术或化疗后未控复发18例。共接受62疗程化疗 ,平均2疗程。[结果]总反应率58.1 % ,其中周疗组66.7% ,月疗组50.0 %。副反应以血液毒性白细胞中度下降为主 ,Ⅲ、Ⅳ级仅占16.1% ,血红蛋白、血小板下降较轻 ,非血液学毒性脱发、肌肉关节痛、感觉异常常见。两组间血液毒性、非血液毒性发生率无差异 ,但周疗组毒性强度低。[结论]紫杉醇周疗与月疗治疗卵巢上皮癌均能取得较好疗效 ,而周疗组略显优势 ,毒性强度较低 ,更易于耐受
[Objective] To investigate the curative effect and toxicity of paclitaxel combined with platinum-based chemotherapy and monthly therapy on epithelial ovarian cancer. [Methods] From February 2000 to December 2000, 31 patients with advanced epithelial ovarian cancer were enrolled. Among them, 15 cases were treated with weekly injection of Taxol 60mg / m2 ~ 80mg / m2 intravenously for 3 weeks and 1 week rest for 1 week Treatment, monthly therapy in 16 cases, Taxol135mg / m2 ~ 175mg / m2 intravenous infusion of 4 weeks repeated, platinum use the same two groups, PDD70mg / m2 or CBPAUC4 ~ 5,4 weeks repeat. The first treatment in 13 cases, 18 cases were not controlled recurrence after surgery or chemotherapy. A total of 62 courses of chemotherapy were received, with an average of 2 courses. [Results] The overall response rate was 58.1%, of which 66.7% in the peripheral treatment group and 50.0% in the monthly treatment group. Side effects of hematotrophic leukocyte moderate decline, Ⅲ, Ⅳ grade accounted for only 16.1%, hemoglobin, platelet loss was less non-hematological toxic hair loss, muscle and joint pain, sensory abnormalities common. There was no difference in the incidence of hematotoxicity and non-hematologic toxicity between the two groups, but the toxicity intensity of the peripheral treatment group was low. [Conclusion] paclitaxel weekly and monthly treatment of ovarian epithelial cancer can achieve better curative effect, while the treatment group slightly superior, lower toxicity and more tolerable